Guidance for Pacira Pharmaceuticals (PCRX)
| Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
|---|---|---|---|---|---|---|
| 2026 | N/A | N/A | $745.00M – 770.00M | $792.20M | = Maintained | Details |
| 2025 | N/A | N/A | $725.00M – 735.00M | $737.20M | = Maintained | Details |
| 2025 | N/A | N/A | $730.00M – 750.00M | $742.80M | = Maintained | Details |
| 2025 | N/A | N/A | $725.00M – 765.00M | $752.90M | = Maintained | Details |
| 2025 | N/A | N/A | $725.00M – 765.00M | $747.60M | = Maintained | Details |
| 2024 | N/A | N/A | $680.00M – 705.00M | $695.40M | = Maintained | Details |
| 2024 | N/A | N/A | $680.00M – 705.00M | $716.60M | = Maintained | Details |
| 2020 | N/A | N/A | $485.00M – 500.00M | $495.91M | = Maintained | Details |
| 2018 | N/A | N/A | $320.00M – 325.00M | $317.47M | = Maintained | Details |
| Q4 2018 | N/A | N/A | $325.00M – 330.00M | $326.84M | = Maintained | Details |
| Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
| 2011 | N/A | N/A | $14.00M – 16.00M | $15.50M | = Maintained | Details |
| 2011 | N/A | N/A | $14.00M – 16.00M | $19.30M | = Maintained | Details |
